Australian (ASX) Stock Market Forum

CSL - CSL Limited

LOL Buy on the rumor sell on the fact.
Bloomberg in their announcement boast that the half year results beat the experts expectations.
well i don't know what they were expecting , but the results weren't bad ( if memory serves me correctly up more than 10% in several areas )

maybe the analysts should pawn their rose-coloured glasses
"Dampened Near Term Growth Aspirations" for the recent acquisition

Vifor’s Injectafer intravenous iron deficiency treatment is facing competition from generic competitors as well as a budget-driven policy in the US that encourages doctors to promote cheaper treatments such as oral iron or a lower-dose injectable iron.

CSL was well-prepared for the generic competition but the regulatory headwinds had, for the time being, outweighed a potential “tailwind” from Injectafer being prescribed for heart failure, which would not be subject to the same budgetary constraint
, CSL chief executive Paul McKenzie said.
and trading down 3 per cent, a bit above $280 a share

coming back up ... $287.

The core business of CSL Behring is the separation of human blood into components such as immunoglobulin from which it makes life-saving treatments for chronic immune system and bleeding disorders such as haemophilia. Seqirus is the second-largest part of CSL. Together, these account for about seven-eighths of CSL’s $US8.053 billion sales and $US3.787 billion group operating profit.

Vifor accounts for the remaining one-eighth of CSL’s sales and earnings, and kidney treatments less than half of that. Still, news this week that CSL had “dampened” its near term outlook for this business knocked several per cent off the shares.

CSL chief executive Paul McKenzie has no regrets about the buy:
“We integrated them – no disruption to the business, $US2 billion in sales, good margin, lots of things to be happy with in a 12 month window. So we just need to bring the whole ecosystem together to really drive the ultimate value."
CSL reported the failure of the AEGIS-II trial, which impacted the share price. Follwed up with a positive annaul report but share price still down for the month.

The following is a post I made a few hours ago in another Chat Room - thought some CSL tragics here may be interested....


Crawling back into The Cave now..
CSL prices US$1.25 billion in Corporate Bonds

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces it has priced US$1.25 billion corporate bonds in the United States 144A / Reg S market.
The notes will be issued by CSL Finance Plc and guaranteed by the parent company, CSL Limited, and certain of its subsidiaries.
The principal amount, tenor and coupon for the notes are:
• US$500m 10-year at a fixed rate coupon of 5.106%
• US$750m 30-year at a fixed rate coupon of 5.417%

CSL intends to use the cash proceeds from the offering to refinance existing bank debt and the remainder for general corporate purposes.
Settlement of the notes is expected to occur on 3 April 2024, subject to customary closing conditions.

i do not hold this share
CSL which is a quality company is struggling as a pick for the 2024 comp. I am still hopeful over the year to get some steady growth.